All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries

Abstract

BACKGROUND: Patients with venous thromboembolism (VTE) are at increased risk of developing recurrent VTE and post-thrombotic syndrome (PTS), a complication of deep vein thrombosis (DVT) characterized by venous reflux and residual venous obstruction that may manifest as chronic pain and swelling. Therefore, formulary/policy decision makers should understand the clinical and economic consequences associated with VTE.

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective

“…Among commercially and Medicare insured patients who experienced an initial VTE event, the Lefebvre et al (2012). 15 One explanation for the greater VTE recurrence rates among our study populations is that we included ER visits in our definition of an acute VTE event, which were not included in the Lefebvre et al study.…”

“…Among commercially and Medicare insured patients who experienced an initial VTE event, the Lefebvre et al (2012). 15 One explanation for the greater VTE recurrence rates among our study populations is that we included ER visits in our definition of an acute VTE event, which were not included in the Lefebvre et al study. 15 VTE recurrence rates in the commercial and Medicare populations were similar to the 14.3% rate of hospital readmission for VTE among patients with VTE as a secondary diagnosis reported by Spyropoulos and Lin.…”

“…15 One explanation for the greater VTE recurrence rates among our study populations is that we included ER visits in our definition of an acute VTE event, which were not included in the Lefebvre et al study. 15 VTE recurrence rates in the commercial and Medicare populations were similar to the 14.3% rate of hospital readmission for VTE among patients with VTE as a secondary diagnosis reported by Spyropoulos and Lin. 10 Other less recent studies have reported VTE recurrence rates to range between 7.0% and 14.0%.…”

Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations

“…Khorana et al reported that in the USA, VTE in a cancer patient entails substantially increased additional hospital costs and more extensive and longer patient care than for a cancer patient without VTE, with average hospital costs 2.9 times higher [9]. In another US study, a general population experiencing VTE was compared with a population without VTE in a real-life setting from 2004 to 2008 [16]. This study showed an annual cost differential per patient, all costs combined, of more than $15,941 (95 % CI, $14,819-$17,012).…”

Inpatient Resource Use and Cost Burden of Deep Vein Thrombosis and Pulmonary Embolism in the United States

“…2 After initial hospitalization, the risk of recurrence of both DVT and PE remains high, with up to 25% of patients experiencing a recurrence within 5 years. 4,5 With recurrence comes the risk of life-threatening complications, including post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension. 1,4,6 A number of studies have reported the economic burden of DVT and PE.…”